| VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma J Zhang, T Wu, J Simon, M Takada, R Saito, C Fan, XD Liu, E Jonasch, ... Science 361 (6399), 290-295, 2018 | 140 | 2018 |
| VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ... Cancer discovery 7 (11), 1284-1305, 2017 | 131 | 2017 |
| Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity WF Ooi, M Xing, C Xu, X Yao, MK Ramlee, MC Lim, F Cao, K Lim, D Babu, ... Nature communications 7 (1), 12983, 2016 | 129 | 2016 |
| Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma ML Nairismägi, ME Gerritsen, ZM Li, GC Wijaya, BKH Chia, Y Laurensia, ... Leukemia 32 (5), 1147-1156, 2018 | 61 | 2018 |
| Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits X Yao, AD Choudhury, YJ Yamanaka, VA Adalsteinsson, TM Gierahn, ... Integrative biology 6 (4), 388-398, 2014 | 52 | 2014 |
| Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ... Cancer discovery 7 (6), 630-651, 2017 | 50 | 2017 |
| Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma WF Ooi, AM Nargund, KJ Lim, S Zhang, M Xing, A Mandoli, JQ Lim, ... Gut 69 (6), 1039-1052, 2020 | 46 | 2020 |
| HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer C Xu, WF Ooi, A Qamra, J Tan, BYJ Chua, SWT Ho, K Das, ZFA Isa, Z Li, ... Gut 69 (2), 231-242, 2020 | 33 | 2020 |
| An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance TJ Hagenbeek, JR Zbieg, M Hafner, R Mroue, JA Lacap, NM Sodir, ... Nature Cancer 4 (6), 812-828, 2023 | 30 | 2023 |
| CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti‐tumor response DT Le, BH Ladle, T Lee, V Weiss, X Yao, A Leubner, TD Armstrong, ... International journal of cancer 129 (3), 636-647, 2011 | 30 | 2011 |
| Tumor cells are dislodged into the pulmonary vein during lobectomy X Yao, C Williamson, VA Adalsteinsson, RS D'Agostino, T Fitton, ... The Journal of thoracic and cardiovascular surgery 148 (6), 3224-3231. e5, 2014 | 23 | 2014 |
| Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells X Yao, M Labelle, CR Lamb, JM Dugan, CA Williamson, DR Spencer, ... International journal of cancer 133 (12), 2925-2933, 2013 | 22 | 2013 |
| Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines VA Adalsteinsson, N Tahirova, N Tallapragada, X Yao, L Campion, ... Integrative biology 5 (10), 1272-1281, 2013 | 20 | 2013 |
| Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ... The Journal of clinical investigation 130 (6), 3005-3020, 2020 | 15 | 2020 |
| VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7: 1284–1305. doi: 10.1158/2159-8290 X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ... CD-17-0375.[Abstract][CrossRef][Google Scholar], 0 | 14 | |
| RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer P Deng, Z Wang, J Chen, S Liu, X Yao, S Liu, L Liu, Z Yu, Y Huang, ... The Journal of Clinical Investigation 132 (22), 2022 | 10 | 2022 |
| Chromatin rewiring by mismatch repair protein MSH2 alters cell adhesion pathways and sensitivity to BET inhibition in gastric cancer AM Nargund, C Xu, A Mandoli, A Okabe, GB Chen, KK Huang, T Sheng, ... Cancer Research 82 (14), 2538-2551, 2022 | 8 | 2022 |
| Epigenomic consequences of coding and noncoding driver mutations X Yao, M Xing, WF Ooi, P Tan, BT Teh Trends in Cancer 2 (10), 585-605, 2016 | 8 | 2016 |
| Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer J Liang, ER Ingalla, X Yao, BE Wang, L Tai, J Giltnane, Y Liang, ... Science Translational Medicine 14 (663), eabo5959, 2022 | 7 | 2022 |
| Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer S Liu, Q Zou, JP Chen, X Yao, P Guan, W Liang, P Deng, X Lai, J Yin, ... The Journal of Clinical Investigation 131 (20), 2021 | 7 | 2021 |
J. Christopher LoveProfessor of Chemical Engineering, MITVerified email at mit.edu
